Immunex Decision On Continuing Enbrel CHF Program Awaits Data Analysis

Immunex' decision on whether to continue development of Enbrel for congestive heart failure awaits a more complete analysis of the data from two halted pivotal trials.

More from Archive

More from Pink Sheet